153 related articles for article (PubMed ID: 35399933)
1. Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients.
Papadopoulos S; Koulouris P; Royer-Chardon C; Tsoumakidou G; Dolcan A; Cherix S; Matter M; Omoumi P; Digklia A
Front Endocrinol (Lausanne); 2022; 13():794512. PubMed ID: 35399933
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A
Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
[No Abstract] [Full Text] [Related]
5. Treatment of Orbital Desmoid-type Fibromatosis With Sorafenib.
Downie EM; Amend CE; Miranda A; Burkat CN
Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):e144-e147. PubMed ID: 35470290
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
Tsukamoto S; Takahama T; Mavrogenis AF; Tanaka Y; Tanaka Y; Errani C
Musculoskelet Surg; 2023 Mar; 107(1):7-18. PubMed ID: 35150408
[TBL] [Abstract][Full Text] [Related]
7. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
[TBL] [Abstract][Full Text] [Related]
8. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
Ioannou M; Demertzis N; Iakovidou I; Kottakis S
Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
10. Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study.
Kwon J; Lee JH; Lee YH; Lee J; Ahn JH; Kim SH; Kim SH; Kim TI; Yun KH; Park YS; Kim JE; Lee KS; Choi JK; Kim HS
Cancer Res Treat; 2022 Oct; 54(4):1240-1255. PubMed ID: 35038826
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs Z; Messiou C; Wong HH; Hatcher H; Miah A; Zaidi S; van der Graaf WT; Judson I; Jones RL; Benson C
Anticancer Drugs; 2017 Apr; 28(4):421-426. PubMed ID: 28099210
[TBL] [Abstract][Full Text] [Related]
12. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Skubitz KM; Manivel JC; Clohisy DR; Frolich JW
Cancer Chemother Pharmacol; 2009 Aug; 64(3):635-40. PubMed ID: 19404642
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of mammary desmoid-type fibromatosis: which benefit?
Scheer L; Lodi M; Molière S; Kurtz JE; Mathelin C
World J Surg Oncol; 2017 Apr; 15(1):86. PubMed ID: 28420393
[TBL] [Abstract][Full Text] [Related]
14. Current management and recent progress in desmoid tumors.
Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
16. Desmoid-type fibromatosis: toward a holistic management.
Penel N; Kasper B; van Der Graaf WTA
Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib therapy for desmoid tumors in adolescent and young adult patients.
Agresta L; Kim H; Turpin BK; Nagarajan R; Plemmons A; Szabo S; Dasgupta R; Sorger JI; Pressey JG
Pediatr Blood Cancer; 2018 Jun; 65(6):e26968. PubMed ID: 29384266
[TBL] [Abstract][Full Text] [Related]
18. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Rauch G; Limprecht R; Sommer M; Dimitrakopoulou-Strauss A; Pilz L; Haller F; Hohenberger P
Eur J Cancer; 2017 May; 76():60-67. PubMed ID: 28282612
[TBL] [Abstract][Full Text] [Related]
19. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
[TBL] [Abstract][Full Text] [Related]
20. Desmoid-type fibromatosis.
Bertucci F; Gonçalves A; Viens P; Monges G; Dubreuil P
J Neurosurg; 2007 Aug; 107(2):473-5; author reply 475. PubMed ID: 17695408
[No Abstract] [Full Text] [Related]
[Next] [New Search]
